Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2

被引:55
|
作者
Kyzas, PA [1 ]
Stefanou, D [1 ]
Batistatou, A [1 ]
Agnantis, NJ [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Pathol, GR-45110 Ioannina, Greece
关键词
VEGF; VEGFR-2; VEGFR-1; angiogenesis inhibitors;
D O I
10.1038/modpathol.3800295
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Vascular endothelial growth factor is a peptide with well-defined actions on the vasculature and fundamental role in tumor angiogenesis. Its action in vascular endothelium is exerted in a paracrine manner. The immunohistochemical expression of this protein by cancer cells in head and neck squamous cell carcinoma was correlated with increased tumor aggressiveness and poor survival in previous studies. In the past years, an increasing amount of studies demonstrated potential autocrine action of vascular endothelial growth factor in various neoplasms. However, the existence and the impact of such autocrine action in head and neck cancer have not been demonstrated yet. In this retrospective study, we evaluated the expression of vascular endothelial growth factor and its receptors in neoplastic cells, in a cohort of patients with head and neck squamous cell carcinoma, and compared this expression with tumor aggressiveness, clinicopathologic parameters and outcome. High expression of vascular endothelial growth factor was strongly correlated with high expression of vascular endothelial growth factor receptor-2 (but not vascular endothelial growth factor receptor-1) on the cancer cells (P<0.001). The co-overexpression of both the protein and vascular endothelial growth factor receptor-2 was associated with higher tumor proliferation rate (P<0.001). The above co-overexpression also correlated with worse survival (log rank P<0.05) in patients with oral-larynx squamous cell carcinoma. Our results suggest that an autocrine vascular endothelial growth factor loop, mediated via vascular endothelial growth factor receptor-2, probably exists in head and neck squamous cell carcinoma. These observations support the hypothesis that the use of vascular endothelial growth factor receptor-2 inhibitors as adjuvant antiangiogenic therapy might have beneficial effects for these patients, by disrupting both paracrine (endothelial-dependent) and autocrine actions of vascular endothelial growth factor.
引用
收藏
页码:485 / 494
页数:10
相关论文
共 50 条
  • [31] Serum levels of vascular endothelial growth factor in patients with head and neck cancer
    F. Riedel
    Karl Götte
    Joachim Schwalb
    Heiner Wirtz
    Wolfgang Bergler
    Karl Hörmann
    European Archives of Oto-Rhino-Laryngology, 2000, 257 : 332 - 336
  • [32] Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer
    Fang, Carolyn Y.
    Egleston, Brian L.
    Ridge, John A.
    Lango, Miriam N.
    Bovbjerg, Dana H.
    Studts, Jamie L.
    Burtness, Barbara A.
    Einarson, Margret B.
    Klein-Szanto, Andres J. P.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2014, 36 (08): : 1113 - 1119
  • [33] Serum levels of vascular endothelial growth factor in patients with head and neck cancer
    Riedel, F
    Götte, K
    Schwalb, J
    Wirtz, H
    Bergler, W
    Hörmann, K
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2000, 257 (06) : 332 - 336
  • [34] Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema
    Kasahara, Y
    Tuder, RM
    Cool, CD
    Lynch, DA
    Flores, SC
    Voelkel, NF
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (03) : 737 - 744
  • [35] VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 TUMOR EXPRESSION IN PATIENTS WITH ADVANCED LARYNGEAL CANCER AFTER INDUCTION CHEMOTHERAPY FOR ORGAN PRESERVATION
    Rueda, Antonio
    Cazorla, Oscar
    Perez, Lidia
    Alvarez, Martina
    Redondo, Maximino
    Gallego, Elena
    Saez, Maribel
    Antonio Medina, Jose
    Solano, Jose
    Matilla, Alfredo
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2011, 33 (06): : 808 - 816
  • [36] Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells
    Kim, SJ
    Seo, JH
    Lee, YJ
    Yoon, JH
    Choi, CW
    Kim, BS
    Shin, SW
    Kim, YH
    Kim, JS
    ONCOLOGY, 2005, 68 (2-3) : 204 - 211
  • [37] The function of vascular endothelial growth factor
    Nieves, Bonnie J.
    D'Amore, Patricia A.
    Bryan, Brad A.
    BIOFACTORS, 2009, 35 (04) : 332 - 337
  • [38] A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities
    Joukov, V
    Kumar, V
    Sorsa, T
    Arighi, E
    Weich, H
    Saksela, O
    Alitalo, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (12) : 6599 - 6602
  • [39] Vascular endothelial growth factor acts as an autocrine growth factor in human pancreatic cancer.
    Sasaki, T
    Hanada, K
    Tsuchida, A
    Hirata, M
    Iwao, T
    Eguchi, N
    Matsubara, K
    Yamamoto, S
    Kawasaki, Y
    Morinaka, K
    Fujii, K
    Kajiyama, G
    GASTROENTEROLOGY, 1998, 114 (04) : A1177 - A1177
  • [40] Vascular endothelial growth factor is an autocrine growth factor for cardiac myxoma cells
    Sakamoto, H
    Sakamaki, T
    Kanda, T
    Tsuchiya, Y
    Sato, M
    Sato, H
    Oyama, Y
    Sawada, Y
    Tamura, J
    Nagai, R
    Kurabayashi, M
    CIRCULATION JOURNAL, 2004, 68 (05) : 488 - 493